Allogene Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $450.00K, a 29.47% decline year-over-year.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $257.00K, a 62.15% decline year-over-year.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $638.00K, a 25.47% decline year-over-year.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $679.00K, a 11.24% decline year-over-year.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $895.00K, a 41.69% decline from fiscal 2024.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.53M, a 38.50% decline from fiscal 2023.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $2.50M, a 1.42% increase from fiscal 2022.
- Allogene Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $2.46M, a 31.96% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $450.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $895.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $257.00K 10-Q · filed 2025-11-06 | |
| 2025-03-31 | $638.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $1.53M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $679.00K 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $856.00K 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.50M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $765.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $1.73M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $2.46M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $931.00K 10-Q · filed 2023-11-02 | $2.46M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $0.00 10-Q · filed 2022-11-02 | $3.16M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $1.53M 10-Q · filed 2023-11-02 | $3.16M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $3.62M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $1.63M 10-Q · filed 2022-11-02 | $3.62M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-06-30 | $0.00 10-Q · filed 2022-11-02 | $3.39M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-03-31 | $1.98M 10-Q · filed 2022-11-02 | $3.39M derived: sum of 4 quarters · filed 2024-03-14 |
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $2.84M 10-K/A · filed 2024-03-14 |
| 2020-09-30 | $1.41M 10-Q · filed 2021-11-04 | $2.84M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | $2.54M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $1.44M 10-Q · filed 2021-05-05 | $2.54M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $1.78M 10-K · filed 2022-02-23 |
| 2019-09-30 | $1.10M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | |
| 2019-03-31 | $684.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |